7 Children Given Bluebird's Skysona Developed Blood Cancer: Study
Cathie Wood's ARK Sheds Robinhood Stock, Adds to Amazon and Coinbase
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: Here's Why
CRISPR Therapeutics Deserves Its Lofty Valuation Even With Conservative Forecasts
RBC Cuts Price Target on CRISPR Therapeutics to $53 From $60, Keeps Sector Perform Rating
Cathie Wood Stocks (CRSP, SHOP, SQ) Could Actually Be Darn Good Picks
With 66% Ownership of the Shares, CRISPR Therapeutics AG (NASDAQ:CRSP) Is Heavily Dominated by Institutional Owners
Pfizer Withdraws Sickle Cell Drug Oxbryta Over Safety Concerns
Health Canada Approves CASGEVY (Exagamglogene Autotemcel), The First CRISPR/Cas9 Gene-Edited Therapy, For Treatment Of Sickle Cell Disease And Transfusion-Dependent Beta Thalassemia In Patients 12 And Older
CRISPR Therapeutics (NASDAQ:CRSP) Shareholders Have Endured a 59% Loss From Investing in the Stock Three Years Ago
Down 21% This Year, Is CRISPR Therapeutics Stock Still a Buy?
CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know
Gene Editing Therapeutics Market Report 2024, Featuring Profiles of Key Players Allogene Therapeutics, CRISPR Therapeutics, Intellia Therapeutics, Sangamo Therapeutics and Vertex Pharmaceuticals - ResearchAndMarkets.com
CRISPR Therapeutics AG (CRSP): Among the Worst ARK Stocks According to Short Sellers
CRISPR Therapeutics AG (NASDAQ:CRSP) Investors Are Less Pessimistic Than Expected
Why Is CRISPR Therapeutics (CRSP) Down 7.7% Since Last Earnings Report?
Duan Yongping followed Buffett and sold some Apple! The investment giants made big moves in the second quarter.
As for Apple, Buffett, Duan Yongping, and Bridgewater are reducing their stakes, while Jinglin, Hillhouse, and the Norwegian Sovereign Fund are increasing theirs. In general, investment giants are still somewhat wary of tech giants.
Express News | CRISPR Therapeutics AG : Truist Securities Cuts Target Price to $100 From $120
Truist Adjusts Price Target on CRISPR Therapeutics to $100 From $120, Maintains Buy Rating
A Look At The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)